← Human Trials & Peer-Reviewed Studies
Effect of needle-free injection on psychological insulin resistance and insulin dosage in patients with type 2 diabetes
Plain-language guide to PMID 38803476 (2024): crossover randomized controlled trial study of Insulin Aspart and NPH Insulin (isophane), insulin resistance, prediabetes & type 2 diabetes.
Key Facts
- PMID
- 38803476
- Journal
- Frontiers in endocrinology
- Year
- 2024
- Study type
- Randomized Controlled Trial
- Authors
- Wang W et al. (8 authors)
- DOI
- 10.3389/fendo.2024.1379830
What This Study Did, in Plain Language
What Was Tested
Researchers studied Insulin Aspart and NPH Insulin (isophane) in the context of insulin resistance, prediabetes & type 2 diabetes in this randomized controlled trial publication.
Psychological insulin resistance (PIR), which refers to the reluctance of diabetic patients to use insulin, is a frequently encountered clinical issue.
Needle-free injection (NFI) offers advantages in terms of expediting insulin absorption and mitigating adverse reactions related to injection.
Who Took Part
PubMed indexes the participants as adults, middle-aged adults and older adults, both men and women.
Sixty-four patients with T2DM participated in this randomized, prospective, open, crossover study.
How the Study Was Run
The researchers set it up as a randomized and crossover study.
Because people in this Insulin Aspart study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Each person switched between Insulin Aspart and the comparison at some point, usually with a gap in between.
The effects of NFI on PIR were analyzed.
What Was Measured
PubMed files the paper under topics including Diabetes Mellitus, Type 2, Hypoglycemic Agents, Insulin Resistance, Insulin Aspart, Insulin, Blood Glucose and Insulin, Isophane.
The authors tagged it with the keywords blood glucose control, glycemic variability, insulin aspart 30, needle-free injection, psychological insulin resistance and type 2 diabetes mellitus.
What This Means in Plain Language
The paper is a randomized and crossover study of Insulin Aspart and NPH Insulin (isophane) in people with insulin resistance, prediabetes & type 2 diabetes.
Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2024 (Frontiers in endocrinology), a journal based in Switzerland.
More context: the Insulin Aspart compound page and the NPH Insulin (isophane) compound page, Insulin resistance, prediabetes & type 2 diabetes research.
Our Notes on the Compounds
Insulin Aspart: A rapid-acting mealtime insulin analog; brands include NovoLog, NovoRapid and Fiasp.
NPH Insulin (isophane): An intermediate-acting insulin made by combining insulin with protamine; also called isophane or NPH insulin (Humulin N, Novolin N).
Related Pages
- Insulin resistance, prediabetes & type 2 diabetes research
- Insulin Aspart in the library
- NPH Insulin (isophane) in the library
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.